A phase II trial of irinotecan in hormone-refractory prostate cancer

摘要: Irinotecan is a DNA topoisomerase I inhibitor that has wide spectrum of activity against human tumors in both preclinical and clinical studies. To evaluate the efficacy irinotecan hormone-refractory prostate cancer, we conducted phase II study 15 men with metastatic, PSA-progressive disease after primary androgen deprivation. was administered at dose 125 mg/m2 weekly for four weeks followed by two-week rest period; cycles were repeated every six weeks. Response assessed evaluation serial changes serum PSA. None fifteen patients had decline PSA greater than 50%; eight stable as best response. three measurable partial or complete Toxicity primarily hematologic gastrointestinal, 40% requiring modification due to granulocytopenia 20% intravenous fluid supplementation development diarrhea. There no treatment-related deaths. We conclude schedule used this trial does not have significant cancer.